Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
2004 4
2005 57
2006 89
2007 106
2008 116
2009 136
2010 133
2011 144
2012 197
2013 173
2014 190
2015 173
2016 188
2017 203
2018 220
2019 215
2020 268
2021 252
2022 233
2023 258
2024 86

Text availability

Article attribute

Article type

Publication date

Search Results

3,058 results

Results by year

Filters applied: . Clear all
Page 1
LRRK2 in Parkinson disease: challenges of clinical trials.
Tolosa E, Vila M, Klein C, Rascol O. Tolosa E, et al. Nat Rev Neurol. 2020 Feb;16(2):97-107. doi: 10.1038/s41582-019-0301-2. Epub 2020 Jan 24. Nat Rev Neurol. 2020. PMID: 31980808 Review.
One of the most common monogenic forms of Parkinson disease (PD) is caused by mutations in the LRRK2 gene that encodes leucine-rich repeat kinase 2 (LRRK2). ...The discoveries that pathogenic mutations in the LRRK2 gene increase LRRK2 kin …
One of the most common monogenic forms of Parkinson disease (PD) is caused by mutations in the LRRK2 gene that encodes …
LRRK2 and Parkinson's disease: from genetics to targeted therapy.
Sosero YL, Gan-Or Z. Sosero YL, et al. Ann Clin Transl Neurol. 2023 Jun;10(6):850-864. doi: 10.1002/acn3.51776. Epub 2023 Apr 6. Ann Clin Transl Neurol. 2023. PMID: 37021623 Free PMC article. Review.
LRRK2 variants are implicated in both familial and sporadic PD. LRRK2-PD has a generally benign clinical presentation and variable pathology, with inconsistent presence of Lewy bodies and marked Alzheimer's disease pathology. ...As novel therapies targeting …
LRRK2 variants are implicated in both familial and sporadic PD. LRRK2-PD has a generally benign clinical presentation and vari …
The Cell Biology of LRRK2 in Parkinson's Disease.
Usmani A, Shavarebi F, Hiniker A. Usmani A, et al. Mol Cell Biol. 2021 Apr 22;41(5):e00660-20. doi: 10.1128/MCB.00660-20. Print 2021 Apr 22. Mol Cell Biol. 2021. PMID: 33526455 Free PMC article. Review.
Point mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease (PD) and are implicated in a significant proportion of apparently sporadic PD cases. ...Additionally, LRRK2's interaction with the …
Point mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease (PD) …
The In Situ Structure of Parkinson's Disease-Linked LRRK2.
Watanabe R, Buschauer R, Böhning J, Audagnotto M, Lasker K, Lu TW, Boassa D, Taylor S, Villa E. Watanabe R, et al. Cell. 2020 Sep 17;182(6):1508-1518.e16. doi: 10.1016/j.cell.2020.08.004. Epub 2020 Aug 11. Cell. 2020. PMID: 32783917 Free PMC article.
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent cause of familial Parkinson's disease. LRRK2 is a multi-domain protein containing a kinase and GTPase. Using correlative light and electron microscopy, in situ cryo-electron tomogr …
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent cause of familial Parkinson's disease. LRRK2 …
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Jennings D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, Chen JJ, Maciuca R, Fraser K, Mabrouk OS, van de Wetering de Rooij J, Heuberger JAAC, Groeneveld GJ, Borin MT, Cruz-Herranz A, Graham D, Scearce-Levie K, De Vicente J, Henry AG, Chin P, Ho C, Troyer MD. Jennings D, et al. Mov Disord. 2023 Mar;38(3):386-398. doi: 10.1002/mds.29297. Epub 2023 Feb 18. Mov Disord. 2023. PMID: 36807624 Clinical Trial.
BACKGROUND: Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising therapeutic approach for the treatment of Parkinson's disease (PD). ...CONCLUSIONS: At generally safe and well-tolerated doses, BIIB122 achieved substantial peripheral LRRK2 kin …
BACKGROUND: Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising therapeutic approach for the treatment of Parkinson …
Historical Perspective: Models of Parkinson's Disease.
Chia SJ, Tan EK, Chao YX. Chia SJ, et al. Int J Mol Sci. 2020 Apr 2;21(7):2464. doi: 10.3390/ijms21072464. Int J Mol Sci. 2020. PMID: 32252301 Free PMC article. Review.
Parkinson's disease (PD) is the most common movement disorder with motor and nonmotor signs. ...Cellular-based disease model is frequently used because of the ease of manipulation and suitability for large-screen assays. ...
Parkinson's disease (PD) is the most common movement disorder with motor and nonmotor signs. ...Cellular-based disease …
Parkinson's disease: etiopathogenesis and treatment.
Jankovic J, Tan EK. Jankovic J, et al. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808. doi: 10.1136/jnnp-2019-322338. Epub 2020 Jun 23. J Neurol Neurosurg Psychiatry. 2020. PMID: 32576618 Review.
The concept of 'idiopathic' Parkinson's disease (PD) as a single entity has been challenged with the identification of several clinical subtypes, pathogenic genes and putative causative environmental agents. ...The application of glucagon-like peptide one receptor a …
The concept of 'idiopathic' Parkinson's disease (PD) as a single entity has been challenged with the identification of several …
Genetics and Pathogenesis of Parkinson's Syndrome.
Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Ye H, et al. Annu Rev Pathol. 2023 Jan 24;18:95-121. doi: 10.1146/annurev-pathmechdis-031521-034145. Epub 2022 Sep 13. Annu Rev Pathol. 2023. PMID: 36100231 Free PMC article. Review.
Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous, resisting distillation to a single, cohesive disorder. Instead, each affected individual develops a virtually unique form of Parkinson's syndrome. Clinical manifestations c …
Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous, resisting distillation to a single, coh …
Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice.
Singh F, Prescott AR, Rosewell P, Ball G, Reith AD, Ganley IG. Singh F, et al. Elife. 2021 Aug 3;10:e67604. doi: 10.7554/eLife.67604. Elife. 2021. PMID: 34340748 Free PMC article.
Parkinson's disease (PD) is a major and progressive neurodegenerative disorder, yet the biological mechanisms involved in its aetiology are poorly understood. ...This study provides the first in vivo evidence that pathogenic LRRK2 directly impairs basal mitop …
Parkinson's disease (PD) is a major and progressive neurodegenerative disorder, yet the biological mechanisms involved in its …
Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects.
Borsche M, Pereira SL, Klein C, Grünewald A. Borsche M, et al. J Parkinsons Dis. 2021;11(1):45-60. doi: 10.3233/JPD-201981. J Parkinsons Dis. 2021. PMID: 33074190 Free PMC article. Review.
Mitochondrial dysfunction represents a well-established player in the pathogenesis of both monogenic and idiopathic Parkinson's disease (PD). Initially originating from the observation that mitochondrial toxins cause PD, findings from genetic PD supported a contribu …
Mitochondrial dysfunction represents a well-established player in the pathogenesis of both monogenic and idiopathic Parkinson's di …
3,058 results